Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' Net Income towards Common Stockholders fell 41.06% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.15% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Net Income towards Common Stockholders is -$17.7 million, which was up 66.47% from -$52.8 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Net Income towards Common Stockholders registered a high of -$1.5 million during Q2 2021, and its lowest value of -$87.1 million during Q3 2021.
  • Its 3-year average for Net Income towards Common Stockholders is -$19.2 million, with a median of -$16.3 million in 2023.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Net Income towards Common Stockholders crashed by 2,911.34% in 2021, and later soared by 83.38% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$16.0 million in 2021, then grew by 12.99% to -$13.9 million in 2022, then declined by 16.93% to -$16.3 million in 2023, then dropped by 12.32% to -$18.3 million in 2024, then tumbled by 41.06% to -$17.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.